Study of Novel PET Tracer Gallium [68Ga]/ Fluorine [18F] -FAPI-04 in the Diagnosis of Cardiovascular Diseases
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of fibroblast activating protein receptor
imaging agent [68Ga]/ Fluorine [18F] -fibroblast activating protein inhibitor
(68Ga/18F-FAPI-04) in clinical application and to verify its effectiveness in the diagnosis
of cardiovascular diseases.
Phase:
N/A
Details
Lead Sponsor:
Nanjing First Hospital, Nanjing Medical University